Guides, maps, and tools for access planning
These pages collect the maps, clocks, models, and checklists that explain how psychedelic therapies move from clinical evidence toward real patient access.
Use them to check the next practical question: what is approved, who pays, where care happens, and what still has to be built.
Start by question
Different readers need different evidence
A general reader may need the access clock first. A researcher may need the follow-up horizon. A developer or investor may need the reimbursement and delivery constraints.
New to access
Why does approval not equal availability?
Open Europe Access Clocks
Researchers
Which study choices can create access problems later?
Open Trial Design Access Risks
Investors
Where can launch timing or uptake assumptions break?
Open Spravato Access Precedent
Drug developers
What has to be ready before approval becomes access?
Open Launch-Readiness Checklist
Operators
What does a governed clinical service have to include?
Open Clinical Delivery Model
Policy readers
How do clinical and retreat routes differ in accountability?
Open Clinical Care vs Retreat Pathways
Step 1
Evidence
Does the therapy work well enough, and for whom?
Check the clinical evidence, safety profile, and trial pipeline that determine whether a therapy can credibly move toward care.
Trial Follow-Up vs HTA Horizon
A visual explanation of why pivotal endpoints, observed follow-up, and HTA model horizons answer different questions for high-touch psychedelic therapies.
Trial Design Choices That Become Access Risks
A practical map of the protocol choices that can support approval while still leaving payer, delivery, or access questions unresolved.
Step 3
Reimbursement
Who pays, and under what evidence standard?
Understand health technology assessment, coverage decisions, economic evidence, and payer logic that determine whether patients can afford care.
Europe Access Clocks
Explains the time gap between EMA authorization and real access or reimbursement, using country-level WAIT benchmarks and scenario controls.
Netherlands HTA Access Clock
A Netherlands-specific explainer for the handoff from EMA authorization to ZiN assessment, possible sluis placement, NZa payment design, and practical access.
Psilocybin HTA Uncertainties
A payer-facing map of the clinical, economic, and implementation uncertainties that remain even when psilocybin-assisted therapy shows a positive clinical endpoint.
Psychedelic Therapy Payment Bundle
A service-component map and interactive payment model for reimbursing the medicine, dosing day, therapist time, monitoring, registry work, and follow-up.
Psychedelic Therapy Cost-Effectiveness Model
A reusable cost-utility, cost-effectiveness, and cost-benefit engine for psychedelic-assisted therapy, with illustrative parameter packs, evidence-status labels, and country HTA lenses.
Spravato Access Precedent
A comparator resource for how esketamine moved from EU authorization into different national access outcomes, and what that teaches for psilocybin-assisted therapy.
Real-World Evidence and Registry Design
A registry-design resource for the post-approval evidence questions that trials and economic models rarely settle on their own.
Group Therapy Economics and Implementation
A first-pass resource on when group formats may improve access, when they may add governance burden, and how payment and evidence questions change.
Are Reimbursement Pathways Ready for Licensed Psychedelic Therapies in Europe?
ICPR 2026 talk page with the recording, downloadable slides, slide-by-slide text, and links into Road to Access guides.
Payer Evidence Checklist for Psychedelic Therapies
A practical checklist for the evidence payers need beyond clinical efficacy: value, uncertainty, implementation, and post-approval evidence.
The Personnel-Hours Question in Psychedelic Therapy
An interactive implementation article for estimating how preparation, dosing, integration, and group formats change staff time.
Psychedelic Therapy Access in Europe: Comparison
A country-comparison resource for understanding medical access, reimbursement status, and practical availability across Europe.
Step 4
Delivery
Can the health system deliver it safely at scale?
Look at care models, workforce needs, training, infrastructure, and operational bottlenecks that shape real-world delivery.
Netherlands Psilocybin Access Sites
A map of current Dutch COMP006 trial sites and plausible implementation infrastructure for a future psilocybin-assisted treatment pathway.
Netherlands Psychedelic Therapy Workforce
A Dutch workforce-readiness page and scenario model for turning BIG-registered professionals into practical psychedelic-therapy capacity.
Psychedelic Therapy Launch-Readiness Checklist
A practical Road to Access checklist for turning a positive clinical and regulatory path into reimbursed, governed, and deliverable psychedelic-assisted therapy.
Clinical Delivery Model for Psychedelic Therapy
A governed clinical pathway for psychedelic therapy, from referral and screening through dosing-day care, follow-up, escalation, and outcome reporting.
Referral, Screening, and Triage Pathway
A patient-entry pathway showing how someone can be referred, screened, treated, deferred, redirected, or followed after psychedelic therapy.
Training and Credentialing for Psychedelic Therapy
A governance resource separating training, credentialing, supervision, fidelity monitoring, professional authorization, and site accountability.
Step 5
Access
Who actually receives care, and who is left out?
Track affordability, equity, underserved populations, and global access questions that determine whether implementation is fair.
Clinical Care vs Retreat Pathways
A scenario resource for Marieke's access choices: clinical care, trials, private specialist care, retreat access, self-directed use, or waiting in standard care.
Country Launch-Readiness Scorecard Methodology
How Blossom reads country-level evidence, access, reimbursement, delivery, ecosystem, and source-review signals when interpreting launch readiness.